Journal
Nature Communications
Publication Date
2017
Volume
8
Document Type
Open Access Publication
DOI
10.1038/ncomms14864
Rights and Permissions
Huang, K.-l. et al. Proteogenomic integration reveals therapeutic targets in breast cancer xenografts. Nat. Commun. 8, 14864 doi: 10.1038/ncomms14864 (2017). This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ Copyright The Author(s) 2017
Recommended Citation
Huang, Kuan-lin; Li, Shunqiang; Cao, Song; Yoon, Christopher; Wyczalkowski, Matthew A.; Erdmann-Gilmore, Petra; Snider, Jacqueline E.; Hoog, Jeremy; Niu, Beifang; Guo, Zhanfang; Sun, Sam Qiancheng; Sanati, Souzan; Scott, Adam; Ye, Kai; McLellan, Michael D.; Wendl, Michael C.; Held, Jason M.; Davies, Sherri R.; Ma, Cynthia; Townsend, R. Reid; Ding, Li; and et al, "Proteogenomic integration reveals therapeutic targets in breast cancer xenografts." Nature Communications. 8, (2017).
https://digitalcommons.wustl.edu/open_access_pubs/5799
Supplementary Figures
Supplementary Data 1.xlsx (54 kB)
Clinical information of the 24 originating breast tumors included in this study.
Supplementary Data 2.xlsx (27 kB)
The coverage of global profiling of the 24 breast cancer patient-derived xenografts.
Supplementary Data 3.xlsx (5338 kB)
iTRAQ global proteome analysis of human proteins.
Supplementary Data 4.xlsx (1905 kB)
LFQ global proteome analysis of human proteins.
Supplementary Data 5.xlsx (29646 kB)
iTRAQ global phosphosite analysis.
Supplementary Data 6.xlsx (61 kB)
PAM50 gene markers used for the hierarchical clustering analysis in the resulting order.
Supplementary Data 7.xlsx (193 kB)
iTRAQ protein markers used for the hierarchical clustering analysis in the resulting order.
Supplementary Data 8.xlsx (84 kB)
LFQ protein markers used for the hierarchical clustering analysis in the resulting order.
Supplementary Data 9.xlsx (352 kB)
iTRAQ mouse stromal protein markers used for the hierarchical clustering analysis in the resulting order.
Supplementary Data 10.xlsx (624 kB)
iTRAQ phosphosite markers used for the hierarchical clustering analysis in the resulting order.
Supplementary Data 11.xlsx (925 kB)
Differential expression analysis between 24 PDX and 77 breast tumors. The top 133 human protein markers with t-test FDR >= 0.3 were selected for joint proteomic clustering analysis.
Supplementary Data 12.xlsx (1046 kB)
Differential expression analysis of basal and luminal B breast tumor PDXs.
Supplementary Data 13.xlsx (53 kB)
Significantly differentially-expressed Reactome pathways (FDR >= 0.01) identified through differential expression of basal and luminal B breast tumor PDXs using Reactome pathways.
Supplementary Data 14.xlsx (51 kB)
Significantly activated pathways (FDR >= 0.01) identified through pathway phosphorylation enrichment analysis.
Supplementary Data 15.xlsx (17 kB)
Potentially druggable genes and their corresponding drugs.
Supplementary Data 16.xlsx (11 kB)
Identified druggable events in 24 breast cancer patient-derived xenografts across DNA, RNA, and protein levels.
